Mallinckrodt (NYSE:MNK) Q3 results:
Sales: $743.7M (-7.0%).
Key product sales: Acthar gel: $229.8M (-20.8%); Inomax: $136.8M (+2.7%).
Net loss: ($1.1M) (-101.0%); non-GAAP net income: $174.5M (-8.6%); loss/share: ($0.01) (-100.7%); non-GAAP EPS: $2.07 (-8.0%).
2019 guidance: EPS: $8.50 – 8.70 from $8.40 – 8.70.
Shares down 2% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.